NCT04290195View on ClinicalTrials.gov

Use of Ziv Aflibercept in Different Retinal Diseases

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

December 1, 2019

Study Completion Date

January 1, 2020

Conditions
Central Retinal Vein Occlusion With Macular Edema
Interventions
DRUG

Ziv-Aflibercept 25 MG/ML [Zaltrap]

Intravitreal injection of 1.25 mg of ziv aflibercept in patients

Trial Locations (1)

31111

Tanta University, Tanta

All Listed Sponsors
collaborator

Tanta University

OTHER

lead

Amin El Sayed Nawar

OTHER

NCT04290195 - Use of Ziv Aflibercept in Different Retinal Diseases | Biotech Hunter | Biotech Hunter